Contact Volker

Speaking Engagements

  

With two prostate cancer-focused approvals in the last year, RLT is finally getting the attention it deserves from investors, biotech, and the wider oncology field. Though still the 3rd line of exotic therapy, the ever-growing pipeline of therapeutics is set to deliver new life-saving therapeutics to patients with various unmet oncological needs.

26-28 July 2022